...
首页> 外文期刊>BMC Infectious Diseases >Epidemiology of Ventilator-Associated Pneumonia, microbiological diagnostics and the length of antimicrobial treatment in the Polish Intensive Care Units in the years 2013-2015
【24h】

Epidemiology of Ventilator-Associated Pneumonia, microbiological diagnostics and the length of antimicrobial treatment in the Polish Intensive Care Units in the years 2013-2015

机译:呼吸机相关肺炎的流行病学,微生物诊断与2013 - 2015年波兰重症监护单位中的抗菌治疗长度

获取原文
           

摘要

Ventilator-associated pneumonia (VAP) is a common nosocomial infection in intensive care units (ICUs). The objective of this study was to describe the epidemiology and microbiology of VAP in Polish ICUs from 2013 to 2015, as well as to understand how these depended on the diagnostic methods used to identify VAP pathogens and the clinical strategy for VAP treatment. This observational study was carried out in seven Polish adult ICUs. VAP surveillance was based on the European Healthcare-associated Infections Surveillance Network recommendations and was defined as pneumonia occurring more than 48?h after receiving mechanical ventilation, with symptom onset 3?days or more after the hospital stay. Depending on the microbiological diagnostic method, VAP cases were classified as PNEU-1 (positive quantitative culture from minimally contaminated lower respiratory tract specimen such as broncho-alveolar lavage, protected brush or distal protected aspirate) or other VAP cases. The incidence of VAP was 8.0% and the incidence density: 12.3/1000 ventilator days. Microbiological diagnosis was made using PNEU-1 in 80 cases (39%); over the study duration, the proportion of cases diagnosed with PNEU-1 increased from 14 to 60% (p??0.001). The predominant etiologic agents causing VAP were Enterobacteriaceae (32.6%) and non-fermenting Gram-negative bacteria (27.6%). The causative microbe varied significantly depending on the diagnostic method: in cases diagnosed using PNEU-1, Staphylococcus aureus (21.3%) and Klebsiella pneumoniae (12.5%) were the dominant organisms, whereas in other VAP cases, Acinetobacter baumannii (23.8%) was commonly observed. The length of antibiotic treatment in cases diagnosed with PNEU-1 was shorter than for other VAP cases (7.2 vs. 9.1?days, p??0.005), as was the duration of hospitalization (49 vs. 51.8?days, p??0.001). Antibiotic resistance was a particular concern for A.baumannii isolates, which were highly resistance to imipenem (70.6%) and meropenem or doripenem (52.9%). K. pneumoniae isolates demonstrated resistance to ampicillin (90.3%), ceftazidime (71.0%) and third-generation cephalosporins (74.2%). A change over time was observed in the microbiological diagnostic methods used for patients with VAP. A. baumannii was observed mainly in VAP cases diagnosed using substandard methods (non-PNEU-1). The duration of treatment for VAP patients diagnosed properly using PNEU-1 was shorter.
机译:呼吸机相关的肺炎(VAP)是重症监护单位(ICU)中常见的医院感染。本研究的目的是从2013年至2015年描述波兰德卢布的VAP流行病学和微生物学,以及了解这些如何取决于用于识别VAP病原体的诊断方法和VAP治疗的临床策略。该观察性研究是在七个波兰成年人ICU中进行的。 VAP监视基于欧洲医疗保健相关的感染监测网络建议,被定义为肺炎接受机械通气后的肺炎,症状出现3?在住院后的3天或更长时间。根据微生物诊断方法,VAP病例被归类为PNEU-1(来自微量污染的下呼吸道样本的阳性定量培养,如支气管 - 肺泡灌洗,保护刷或远端保护吸气)或其他VAP病例。 VAP的发生率为8.0%,发病密度:12.3 / 1000呼吸机。使用PNEU-1在80例(39%)中进行微生物诊断;在研究持续时间内,患有PNEU-1诊断的病例的比例从14〜60%增加(p?<0.001)。导致VAP的主要病因试剂是肠杆菌(32.6%)和非发酵革兰氏阴性细菌(27.6%)。原因微生物根据诊断方法而显着变化:在使用PNEU-1诊断的情况下,金黄色葡萄球菌(21.3%)和Klebsiella肺炎(12.5%)是显性生物,而在其他VAP病例中,鲍曼菌(23.8%)是通常观察到。患有PNEU-1的病例中的抗生素治疗的长度比其他VAP病例短(7.2与9.1?天,P?0.005),如住院期的持续时间(49对51.8?天,P? <?0.001)。抗生素抗性是A.Baumannii分离株的特别关注,其对亚氨植物(70.6%)和梅洛尼姆或多翅片(52.9%)的抗性高度抗性。 K.肺炎群落分离物证明对氨苄青霉素(90.3%),头孢他啶(71.0%)和第三代头孢菌素(74.2%)的抗性。在用于VAP患者的微生物诊断方法中观察到随时间的变化。 A. Paumannii主要在使用不合标准方法(非PNEU-1)诊断的VAP病例中。使用PNEU-1正确诊断的VAP患者的治疗持续时间更短。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号